| | Business Summary | | Lynx
Therapeutics,
Inc.
is
engaged
in
the
development
and
application
of
novel
technologies
for
the
discovery
of
gene
expression
patterns
and
genomic
variations
important
to
the
pharmaceutical,
biotechnology
and
agricultural
industries.
These
technologies
are
based
on
Megaclone,
the
Company's
proprietary
cloning
procedure.
The
Company
has
developed
a
suite
of
applications
that
have
the
potential
to
enhance
the
pace,
scale
and
quality
of
genomics
and
genetics
research
programs.
Megaclone
transforms
a
sample
containing
millions
of
DNA
molecules
into
one
made
up
of
millions
of
micro-beads,
each
of
which
carries
approximately
100,000
copies
of
one
of
the
DNA
molecules
in
the
sample.
The
Company
can
capture,
on
one
set
of
micro-beads,
clones
of
nearly
all
the
DNA
sequences
that
characterize
a
sample.
Once
attached
to
the
micro-beads,
these
clones
can
be
handled
and
subjected
to
experiments
and
analyses
all
at
the
same
time. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Lynx
Therapeutics
is
engaged
in
the
development
and
application
of
novel
technologies
for
the
discovery
of
gene
expression
patterns
and
genomic
variations
important
to
the
pharmaceutical,
biotechnology
and
agricultural
industries.
For
the
six
months
ended
6/30/01,
revenues
rose
33%
to
$7.8
million.
Net
loss
totalled
$10.3
million,
up
from
$3.6
million.
Revenues
reflect
an
increase
in
technology
access
and
service
fees.
Higher
loss
reflects
the
absence
of
a
$3.1
million
investment
gain. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Craig Taylor, 50
Chairman | -- | -- | Norman Russell, Ph.D., 48
Pres,
CEO, Director | $263K | -- | Edward Albini, 43
CFO
and Sec. | 197K | -- | Stephen Macevicz, Ph.D., 51
VP,
Intellectual Property | 192K | $860K | William Wong, Ph.D., 52
VP-Bus.
Devel. | -- | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/l/lynx.gif)